Biquelle XL is a prolonged-release tablet of quetiapine indicated for the:¹

Schizophrenia and medication adherence

The recommended daily dose, for the treatment of schizophrenia and moderate to severe manic episodes of bipolar disorder, is 600 mg, of quetiapine.¹

Adherence to medication is essential for the alleviation of symptoms, with effective management of schizophrenia still remaining a significant challenge to clinicians.^2-5 Approximately 70-80% of persons with schizophrenia find treatment with first-line antipsychotic medications effective, however, an estimated 50% of those who respond well to medications are non-adherent to treatment regimen.^2-5

The recommended daily dosage for treatment of schizophrenia currently necessitates taking two Quetiapine XL 300mg tablets.^1,2 Biquelle XL offers a 600mg once a day tablets regime, which may benefit some individual patients with compliance, concordance and adherence to treatment. .^2-5

Available as:

Biquelle XL is bioequivalent to Seroquel (quetiapine) XL tablets (Luye Pharma Limited, London, UK).⁶

Biquelle XL could offer significant cost savings to your practice and integrated care system/board (ICS/B).

Quetiapine 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets are in category C of the UK Drug Tariffs.⁷

However, the NHS can make up to 56% savings on the cost of category C quetiapine by prescribing Biquelle XL by brand name.^7*

Prescribing Biquelle XL by brand could save the NHS £8.7Million per year versus prescribing quetiapine prolonged release tablets generically.^8**

Biquelle XL is one of Aspire Pharma’s cost saving prolonged-release products.

In addition, Biquelle XL:

*Based on 56% saving when prescribing Biquelle XL 50, 150, 200, 300 and 400mg tablets only, versus the cost of Category C quetiapine XL on the UK Drug Tariffs. ** Annual cost saving based on modelled market quarterly turnover data x 4 surrounding 42 ICS/ICBS reviewing their generic quetiapine prolonged-release tablet prescriptions to Biquelle XL. ***No change in price subject to no material change to the products or Category C of the UK Drug Tariffs until the 2024 VPAS review.

References: 1) Biquelle XL Summary of product characteristics. 2) Peuskens J. (2011). The management of schizophrenia: focus on extended-release quetiapine fumarate. Neuropsychiatric disease and treatment, 7, 549–564. https://doi.org/10.2147/NDT.S3380 (accessed April 2023) 3) Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. The Journal of Clinical Psychiatry, 63(10), 892–909. https://doi.org/10.4088/JCP.v63n1007 (accessed April 2023) 4) Acosta, F. J., Hernández, J. L., Pereira, J., Herrera, J., & Rodríguez, C. J. (2012). Medication adherence in schizophrenia. World journal of psychiatry, 2(5), 74–82. https://doi.org/10.5498/wjp.v2.i5.74. (accessed April 2023) 5) El-Mallakh, P., & Findlay, J. (2015). Strategies to improve medication adherence in patients with schizophrenia: the role of support services. Neuropsychiatric disease and treatment, 11, 1077–1090. https://doi.org/10.2147/NDT.S56107 (accessed April 2023) 6) 1010067149 v 5.0 September 2021 Data on File – Bioequivalence for prolonged-release 7)  UK Drug Tariffs (April 2023) 8) Insypher data: 10100831045 v 13.0 April 2023 CSC XL Range, GPPLPD Date Range: Sep-22 -Nov-22 9) 1010269098 v 16.0 February 2023 Biquelle XL (Quetiapine) Price Guarantee Letter and 1010083058 v 35.0 March 2023 Cost-saving Prolonged-release Range Supply guarantee Letter

BIQ1010269B1_APR2023